COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Legislative items to be unveiled, revised in 2025
- SCO meeting calls on political parties to jointly address global challenges
- Cooperation key to development: Shanghai Forum
- Zhejiang, Hong Kong launch new cooperation mechanism
- Chinese, Vietnamese coast guards complete first joint patrol in Beibu Gulf
- Experts say Xi's new proposals on global climate fight show resolve, bolster faith
